• Mashup Score: 2
    ITM Announces Completion of Conversion into SE - 3 year(s) ago

    ITM, a leading radiopharmaceutical biotech company, announced today with the registration in the Commercial Register of the District Court of Munich, the completion of its conversion from a German stock corporation (Aktiengesellschaft, “AG”) into a European company (Societas Europaea, “SE”). As of September 21, 2021, ITM is operating under the registered name ITM Isotope Technologies Munich SE…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      Today we announced the completion of our conversion into an SE. The transition represents the next logical step in our growth trajectory and further suits ITM’s international position. Please visit: https://t.co/LiiijNROAn https://t.co/13RShqLMqd

  • Mashup Score: 0
    GEP-NET Trials - 3 year(s) ago

    Neuroendocrine tumors are a rare form of cancer and are frequently of gastroenteropancreatic origin (GEP-NETs). GEP-NETs are often asymptomatic and diagnosed at a late stage with metastases and with limited possibility of surgical removal, thus with still high unmet medical need for treatment. COMPETE and COMPOSE are two phase III clinical trials to evaluate Targeted…

    Source: www.itm-gep-net-trials.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      #HealthcareProfessionals from the US seeking info on our phase III #ClinicalTrials for the treatment of GEP-NETs can find an overview of our study designs, inclusion & exclusion criteria, participating centers, investigational #therapeutic agent & more at: https://t.co/gqtEckovBO https://t.co/w2vy1AuK8h

  • Mashup Score: 1
    GEP-NET Trials - 3 year(s) ago

    Neuroendocrine tumors are a rare form of cancer and are frequently of gastroenteropancreatic origin (GEP-NETs). GEP-NETs are often asymptomatic and diagnosed at a late stage with metastases and with limited possibility of surgical removal, thus with still high unmet medical need for treatment. COMPETE and COMPOSE are two phase III clinical trials to evaluate Targeted…

    Source: www.itm-gep-net-trials.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      Are you a #patient or caregiver from the US interested in learning about investigational treatments for #neuroendocrine tumors using Targeted Radionuclide Therapy? Access info about our clinical trials, including participating centers, on our info site: https://t.co/UbO2h9sJ8S https://t.co/XdMSTnJuIH

  • Mashup Score: 1
    Familienfreundliche Unternehmen 2020 - kununu Blog - 3 year(s) ago

    Familienfreundlichste Unternehmen in Deutschland & Österreich 2020 ➡️ zum kununu Ranking ✅.

    Source: kununu Blog
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      Juhu! ITM ist einer der zwei familienfreundlichsten #Arbeitgeber in der Medizin- und Pharmabranche in Deutschland. Vielen Dank an alle KollegInnen für das große Lob und @freundin und @kununu für die Auszeichnung! #hiring https://t.co/9c9XhpsjXT https://t.co/1u4YueclDB

  • Mashup Score: 0
    ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021 - 3 year(s) ago

    ITM AG, a leading radiopharmaceutical company, today announced that it will host a virtual industry satellite symposium titled, “A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy” at the European Society of Medical Oncology (ESMO) Congress 2021. The symposium will feature renowned key opinion leaders in the field…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_AG
      ITM_AG

      ITM to host Virtual Symposium at ESMO 2021 with Key NET Experts on Sep 17, 2021. The symposium containing critical discussions addressing the changes in treatment and diagnosis of NETs will be held on Friday, Sep 17th, 2021, from 10:30am - 12:00pm CEST https://t.co/Gf7I2B4quX https://t.co/S4AiwBVfDM

Load More